雄激素受体在前列腺癌细胞中作用及其靶向治疗的研究进展

雄激素受体(androgen receptor, AR)在前列腺癌的发生发展中扮演重要角色。雄激素剥夺疗法(androgen deprivationtherapy, ADT)早期可成功抑制肿瘤的生长, 但最终导致肿瘤复发并进入激素抵抗阶段。AR对前列腺癌基质细胞起促进肿瘤增殖和转移作用, 是上皮腔样细胞的存活因子, 而对肿瘤干细胞样细胞及上皮基底细胞的增殖起抑制作用, AR在不同类型细胞中的不同作用向当前ADT传统的疗法提出挑战, 为发展新的治疗策略提供理论依据。目前以AR为靶点的靶向治疗药物研发也取得一些进展。本文就AR在前列腺癌不同类型细胞中的作用及靶向治疗方面的进展加以综述。 

Research progress on androgen receptor in prostate cancer cells and related targeted therapy

Androgen receptors(AR) have an important function in the development and progression of prostate cancer.Androgen deprivation therapy(ADT) is successful in suppressing prostate tumor growth; however, the therapy eventually fails, leading to recurrent tumor growth in a hormone-refractory manner.Recent studies indicate that AR acts as a proliferation stimulator for prostatic stromal cells, whereas epithelial AR functions as a survival factor for luminal cells and a suppressor for tumor stem-like cells and epithelial basal cells proliferation.The varying functions of different AR cell types present a severe challenge for current ADT, but provide important bases for treatment strategies.Significant progress has been achieved in targeted therapy for prostate cancer through AR.This article reviews the research developments in the role of AR in the different types of prostate cancer cells and in targeted therapy.